Citation Impact
Citing Papers
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
2011
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
2019
Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa
2010 Standout
Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases
2007 Standout
Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
2014 StandoutNobel
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
2009 Standout
Retinoblastoma-binding protein 2 (RBP2) is frequently expressed in neuroendocrine tumors and promotes the neoplastic phenotype
2016
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
The EGLN-HIF O 2 -Sensing System: Multiple Inputs and Feedbacks
2017 StandoutNobel
Gastric cancer
2016 Standout
Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy
2007
Pancreatic cancer
2004 Standout
Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma
2010
A meta‐analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma†
2009
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
2006 Standout
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS)
2015
Microbial tryptophan catabolites in health and disease
2018 Standout
Pancreatic cancer
2020 Standout
Crohn's Disease–Associated Adherent Invasive Escherichia coli Modulate Levels of microRNAs in Intestinal Epithelial Cells to Reduce Autophagy
2013
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
2009
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
2013 StandoutNature
FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort
2014
Cancer drug resistance: an evolving paradigm
2013 Standout
Advanced pancreatic carcinoma: current treatment and future challenges
2010
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
2012 StandoutNatureNobel
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
2010 StandoutNature
Leptin and cancer
2005
Pancreatic cancer
2016 Standout
Hepatocellular carcinoma
2012 Standout
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Pancreatic Adenocarcinoma
2014 Standout
Colorectal cancer
2019 Standout
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016
Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer
2010
Crohn's disease
2016 Standout
Leptin induces functional activation of cyclooxygenase‐2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells
2008
Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma
2006
Ulcerative colitis
2016 Standout
Update on the treatment of neuroendocrine tumors
2003
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
2013
Gastric cancer
2020 Standout
Molecular mechanisms of cancer development in obesity
2011
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Pancreatic Cancer
2010 Standout
What We Talk About When We Talk About Fat
2014 Standout
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
2015 StandoutNature
Somatostatin Analog Therapy in Treatment of Gastrointestinal Disorders and Tumors
2003
Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
2008
Advanced gastric cancer: Current treatment landscape and future perspectives
2016
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
The butyrate story: old wine in new bottles?
2004
COPII and the regulation of protein sorting in mammals
2011 StandoutNobel
Adipocytokines: mediators linking adipose tissue, inflammation and immunity
2006 Standout
Adipose Tissue as an Endocrine Organ
2004 Standout
Pancreatic cancer
2011 Standout
Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase
2018 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
MicroRNA-155 Promotes Resolution of Hypoxia-Inducible Factor 1α Activity during Prolonged Hypoxia
2011
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Supramolecular Hydrogelators and Hydrogels: From Soft Matter to Molecular Biomaterials
2015 Standout
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review
2002
Chemotherapy for advanced gastric cancer
2017 Standout
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
2017 Standout
Microbiota‐derived tryptophan indoles increase after gastric bypass surgery and reduce intestinal permeability in vitro and in vivo
2017
Human serum leads to differentiation of human hepatoma cells, restoration of very-low-density lipoprotein secretion, and a 1000-fold increase in HCV Japanese fulminant hepatitis type 1 titers
2013 StandoutNobel
Neuroendocrine Tumor‐Targeted Upconversion Nanoparticle‐Based Micelles for Simultaneous NIR‐Controlled Combination Chemotherapy and Photodynamic Therapy, and Fluorescence Imaging
2017
Chemoradiotherapy in the Management of Locally Advanced Pancreatic Carcinoma: A Qualitative Systematic Review
2009
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
2016
Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma
2009
Intracellular Trafficking and Secretion of VLDL
2012
Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2016
European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies
2015
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
2015
Chemodynamic Therapy: Tumour Microenvironment‐Mediated Fenton and Fenton‐like Reactions
2018 Standout
Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies
2007
Tissue-specific expression of B7x protects from CD4 T cell–mediated autoimmunity
2011 StandoutNobel
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
2010
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
2003
Works of Thomas Aparicio being referenced
Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy.
2004
Molecular analysis and intestinal expression of SAR1 genes and proteins in Anderson's disease (Chylomicron retention disease)
2011
Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study
2009
Identification of Restricted Subsets of Mature microRNA Abnormally Expressed in Inactive Colonic Mucosa of Patients with Inflammatory Bowel Disease
2010
Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours
2004
Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours
2001
Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans
2000
FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Entérologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study
2006
Overexpression of gastric leptin precedes adipocyte leptin during high-fat diet and is linked to 5HT-containing enterochromaffin cells
2014
Anderson’s disease (chylomicron retention disease): a new mutation in the SARA2 gene associated with muscular and cardiac abnormalities
2008
Leptin Counteracts Sodium Butyrate-induced Apoptosis in Human Colon Cancer HT-29 Cells via NF-κB Signaling
2004
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
1999
Leptin reduces the development of the initial precancerous lesions induced by azoxymethane in the rat colonic mucosa
2004
Small bowel adenocarcinoma: Epidemiology, risk factors, diagnosis and treatment
2013
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study
2008
PRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma
2017
FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).
2018
Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study
2006
Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study
2014
Use of bevacizumab in elderly patients with metastatic colorectal cancer: Review
2010